We are live on ! Find out more
ELTX icon

Elicio Therapeutics
ELTX

18 hedge funds and large institutions have $2.8M invested in Elicio Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

20% more funds holding

Funds holding: 15 → 18 (+3)

3% more capital invested

Capital invested by funds: $2.71M → $2.8M (+$81.5K)

0.54% more ownership

Funds ownership: 3.41% → 3.94% (+0.54%)

Holders
18
Holders Change
+3
Holders Change %
+20%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$665K
2
Millennium Management
Millennium Management
New York
+$194K
3
Citadel Advisors
Citadel Advisors
Florida
+$154K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$35.3K
5
MHC
Meyer Handelman Company
New York
+$6.29K

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$618K
2
UBS Group
UBS Group
Switzerland
-$5.99K
3
TRCT
Tower Research Capital (TRC)
New York
-$1.25K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.19M +$665K +69,777 +99%
CM
2
CM Management
Florida
$549K – – –
NCM
3
Nantahala Capital Management
Connecticut
$254K -$618K -64,939 -68%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$236K +$35.3K +3,705 +15%
Millennium Management
5
Millennium Management
New York
$172K +$194K +20,380 New
Citadel Advisors
6
Citadel Advisors
Florida
$137K +$154K +16,206 New
MHC
7
Meyer Handelman Company
New York
$117K +$6.29K +661 +5%
BCM
8
Bridgeway Capital Management
Texas
$106K – – –
Bank of America
9
Bank of America
North Carolina
$14.2K +$914 +96 +6%
SPIA
10
Steward Partners Investment Advisory
New York
$13.1K – – –
Citigroup
11
Citigroup
New York
$3.16K – – –
Carson Wealth (CWM LLC)
12
Carson Wealth (CWM LLC)
Nebraska
$3K – – –
NCM
13
Northwest Capital Management
Oregon
$2.96K – – –
Morgan Stanley
14
Morgan Stanley
New York
$1.33K +$286 +30 +24%
TRCT
15
Tower Research Capital (TRC)
New York
$321 -$1.25K -131 -78%
Wells Fargo
16
Wells Fargo
California
$186 +$67 +7 +47%
UBS Group
17
UBS Group
Switzerland
$135 -$5.99K -629 -98%
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
– +$543 +57 New

ELTX Hedge Fund Activity: Q3 2023 in Review

18 of the 6,304 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q3 2023, worth a combined $2.8M — up 3% from $2.71M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ELTX positions and 0 closed out — a net gain of 3 holders — while 6 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, adding an estimated $665K. The largest seller was Nantahala Capital Management, cutting an estimated $618K.

  • 18 institutional investors held Elicio Therapeutics (ELTX) as of Q3 2023, up from 15 in Q2 2023.
  • Funds reported $2.8M of Elicio Therapeutics stock for Q3 2023, up 3% quarter-over-quarter.
  • 3 funds opened new Elicio Therapeutics positions in Q3 2023 and 0 closed out, a net change of +3 holders.
  • The largest Elicio Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $665K added.
  • The largest Elicio Therapeutics seller in Q3 2023 was Nantahala Capital Management, an estimated $618K sold.

Based on aggregated 13F filings for Q3 2023.